ClinicalTrials.gg
CompletedNCT02561455Updated Nov 19, 2024Results posted

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

A Phase 1/2 interventional study of Gilteritinib in Advanced Solid Tumors and Acute Myeloid Leukemia, sponsored by Astellas Pharma Global Development, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
29th of 31
9 · median 97
Started
2016
with 2 others
Phase 1/2
8 of 31
2 open now
Registered
6th of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 29th largest by enrollment, is one of 3 that started in 2016, is one of 8 in phase 1/2, and was the 6th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.

03

Conditions studied

  • Advanced Solid Tumors
  • Acute Myeloid Leukemia

Keywords

  • Advanced solid tumors
  • Acute myeloid leukemia
  • gilteritinib
  • ASP2215
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must currently be participating in an Astellas sponsored, single agent ASP2215 trial, receiving ASP2215 and have not met any discontinuation criteria of the parent study and can enroll into this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug.
  • Subject must be deriving benefit from continued treatment without any persistent intolerable toxicity from continued treatment of ASP2215.
  • Female subject must either:

    • Be of non-: (defined as at least 1 year without any menses) prior to Screening, or documented surgically sterile or post-hysterectomy (at least 1 month prior to Screening)
    • Or, if of childbearing potential, Agree not to try to become pregnant during the study and for 180 days after the final study drug administration; And have a negative urine pregnancy test at Day 1; And, if heterosexually active, agree to consistently use two forms of highly effective (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 180 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 60 days after the final study drug administration.
  • Female subject must not donate ova starting at Screening and throughout the study period, and for 180 days after the final study drug administration.
  • Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 120 days after the final study drug administration.
  • Male subject must not donate sperm starting at Screening and throughout the study period and, for 120 days after the final study drug administration.
  • Subject agrees not to participate in another interventional study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
  • Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Gilteritinib 40 mg

    Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 80 mg

    Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 120 mg

    Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

    Drug: Gilteritinib

  • Experimental
    Gilteritinib 200 mg

    Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

    Drug: Gilteritinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator.

    Time frame: From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days)

  2. Eastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)

    ECOG performance status was used to assess participants disease progression, and ability to carry out the daily living activities. The participants were graded on a scale of 0 to 5 where 0 = fully active, able to carry on all predisease performance without restriction; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = capable of only limited self-care,confined to bed or chair more than 50% of waking hours; 4 = completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead. Number of participants with ECOG performance status was reported.

    Time frame: EOT Visit (30 days post-last dose, maximum treatement duration of 1067 days)

07

Results

Posted Aug 16, 2021

Participant flow

Participants from previosuly conducted ASP2215 trial were recruited to receive gilteritinib at a dose specified at the time of their end of study visit in the previous ASP2215 study.

Participant flow — Overall Study
MilestoneGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mg
Started2331
Completed0100
Not completed2231
Withdrew: Participant transitioned to commercial drug1121
Withdrew: Withdrawal by subject1010
Withdrew: Disease progression0100

Outcome measures

PrimaryNumber of Participants With Adverse Events

AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator.

Time frame:
From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mg
Number of Participants With Adverse Events2331
PrimaryEastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)

ECOG performance status was used to assess participants disease progression, and ability to carry out the daily living activities. The participants were graded on a scale of 0 to 5 where 0 = fully active, able to carry on all predisease performance without restriction; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = capable of only limited self-care,confined to bed or chair more than 50% of waking hours; 4 = completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead. Number of participants with ECOG performance status was reported.

Time frame:
EOT Visit (30 days post-last dose, maximum treatement duration of 1067 days)
Reported as:
Count of participants · Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)
ParticipantsGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mg
Grade 02000
Grade 10301
Grade 20010
Grade 30000
Grade 40000
Grade 50000

Adverse events

Collected over From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilteritinib 40 mg0/2 (0%)2/2 (100%)2/2 (100%)
Gilteritinib 80 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Gilteritinib 120 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Gilteritinib 200 mg0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mg
AppendicitisInfections and infestations1/20/30/30/1
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20/30/30/1
Obstructive pancreatitisGastrointestinal disorders0/20/31/30/1
PyrexiaGeneral disorders0/20/31/30/1
Respiratory syncytial virus infectionInfections and infestations0/20/31/30/1
Staphylococcal bacteraemiaInfections and infestations0/20/31/30/1
Blood creatine phosphokinase increasedInvestigations0/21/30/30/1
Musculoskeletal painMusculoskeletal and connective tissue disorders0/20/31/30/1
MyositisMusculoskeletal and connective tissue disorders0/21/30/30/1
OsteonecrosisMusculoskeletal and connective tissue disorders0/20/31/30/1
Most frequent other events
Showing 10 of 101
Most frequent other events
EventGilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mg
DiarrhoeaGastrointestinal disorders0/21/32/31/1
ToothacheGastrointestinal disorders0/20/30/31/1
FatigueGeneral disorders1/21/30/31/1
PainGeneral disorders0/20/30/31/1
PyrexiaGeneral disorders0/20/31/31/1
COVID-19Infections and infestations0/20/30/31/1
InfluenzaInfections and infestations1/20/31/31/1
SinusitisInfections and infestations1/20/30/31/1
Foot fractureInjury, poisoning and procedural complications0/20/31/31/1
WoundInjury, poisoning and procedural complications0/20/30/31/1

Baseline characteristics

The analysis population was the safety analysis set (SAF), which consisted of all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Gilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgTotal
Mean47.5 ± 17.741 ± 17.555.7 ± 12.131.046.2 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Gilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgTotal
Female21216
Male02103
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Gilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgTotal
Hispanic or Latino01001
Not Hispanic or Latino22318
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Gilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White23319
More than one race00000
Unknown or Not Reported00000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Gilteritinib 40 mgGilteritinib 80 mgGilteritinib 120 mgGilteritinib 200 mgTotal
Grade 012014
Grade 111305
08

Study locations

7 sites
  • Site US10005
    Phoenix, Arizona 85084, United States
  • Site US10003
    Baltimore, Maryland 21201, United States
  • Site US10006
    New York, New York 10032, United States
  • Site US10007
    New York, New York 10065, United States
  • Site US10001
    Cleveland, Ohio 44195, United States
  • Site US10004
    Hershey, Pennsylvania 17033, United States
  • Site US10008
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jul 2020, 50 months.

Results were first posted in Aug 2021, 1 year after primary completion.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 50 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2015
First posted
Sep 28, 2015
StartActual
May 3, 2016
Primary completionActual
Jul 28, 2020
CompletionActual
Jul 28, 2020
Results first posted
Aug 16, 2021
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02561455
Responsible party
Sponsor
First posted
Sep 28, 2015
Start date
May 3, 2016
Primary completion
Jul 28, 2020
Completion
Jul 28, 2020
Results posted
Aug 16, 2021
Last update
Nov 19, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion